Bruker Installs NMR Metabolic Profiling Systems at Norwegian University of Science & Technology (NTNU) Trondheim for Research...
15 February 2011 - 11:08PM
Business Wire
Bruker has installed two nuclear magnetic resonance (NMR)
spectrometers for metabolic profiling at the new MR Metabolomics
Laboratory at the NTNU hospital campus in Trondheim. Metabolic
profiling of tissue samples and biofluids has the potential to
transform the way cancer diagnostics and treatments are optimized
for individual patients. The new NMR systems will enable scientists
at NTNU’s Faculty of Medicine, working in partnership with
clinicians at St. Olavs University Hospital, to investigate tissue
samples and biofluids from patients taking part in studies, or from
model systems of the same diseases. Researchers will use the NMR
instrumentation for rapid, high-throughput analyses, aiming for
characterisation, treatment planning and monitoring of cancer
patients. The ultimate goal is to investigate whether this
methodology can provide clinicians with more detailed diagnostic
information that can improve treatment for an individual
patient.
New MR Metabolomics Laboratory is located
at the University hospital campus in Trondheim, Norway (Photo:
Business Wire)
To help realize the vision of enhancing patient diagnostics and
treatment, NTNU has partnered with Bruker, the world's leading
provider of NMR spectroscopy instrumentation. NTNU and Bruker have
signed a research collaboration agreement to jointly develop,
optimize and implement NMR cancer diagnostics and prognostic
modelling. One of the goals for the NTNU - Bruker collaboration is
to develop products that will progress MR high-throughput screening
towards a routine clinical setting.
"By combining bioinformatics and medical expertise with advanced
metabolomics technology, NTNU is at the forefront of developing
innovative diagnostic tools for the future," said Dr. Manfred
Spraul, Director of NMR Applications at Bruker in Germany. He
continued: "Bringing metabolic profiling into a hospital setting
with long traditions for developing and integrating new medical
technology is a great start for innovations that potentially can
improve patient care and reduce cost. We look forward to working
with NTNU and the new MR Metabolomics Lab on these
opportunities."
The NTNU MR Metabolomics Laboratory will be headed by Professor
Ingrid S. Gribbestad, a leading researcher in MR technology and
biomolecular medicine. Her research team has worked with MR cancer
tissue characterization for a decade, and has pioneered
characterization of breast cancer using this methodology. Cancer
metabolomics takes into account all of the environmental factors
that influence biology, including drugs, diets, protein activities
and gene expressions. The NMR metabolic fingerprint of each cancer
sample can be obtained in a few minutes, providing a potential
future high-throughput molecular diagnostic tool. The group showed
recently, for the very first time, that combining metabolite
profiles with gene expression profiles from the same sample created
new subclasses of breast cancer with unique characteristics.
Professor Ingrid Gribbestad commented: "Because of the close
links between clinicians and scientists, and the focus on medical
technology, NTNU and St. Olavs University Hospital have created a
unique facility for advances in this field. Here, new technologies
and methods have a short cut to clinical testing.”
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of
high-performance scientific instruments and solutions for molecular
and materials research, as well as for industrial and applied
analysis. For more information: www.bruker.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6610195&lang=en
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024